Levetiracetam Tablet, Film Coated
Product Images NDC 50090-6378

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-6378). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 01)

This text is providing instructions for calculating the total daily dose in mL for a patient based on their weight and the daily dose prescribed in mg/kg/day. The information also mentions a concentration of 100 mg/mL.*

FDA Label Image

Figure 2 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 02)

This appears to be a formula for calculating clearance rate (CLer) in patients based on weight, age, and serum creatinine levels. The formula is adjusted for female patients and then further adjusted for body surface area (BSA). However, no additional context is provided, so it is unclear what this formula is specifically used for or in what medical context.*

FDA Label Image

Structure (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 03)

FDA Label Image

Figure 4 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 04)

This appears to be a graph or chart showing percentages in relation to the use of Levetiracetam medication at different dosages. The dosages mentioned are 1000 mg/day and 3000 mg/day. The percentages seem to be related to the effectiveness or success rate of the medication. The graph is based on data obtained from two groups with N values of 95, 97, and 101. There is not enough information to determine the specific purpose or context of the graph.*

FDA Label Image

Figure 5 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 05)

This appears to be a chart or table showing the percentage of patients in different groups, including a placebo group and two groups taking different doses of a medication called Levetiracetam. The percentages appear to represent some kind of outcome or side effect related to the treatment. Without more context, it is difficult to determine the meaning of the percentages.*

FDA Label Image

Figure 6 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 06)

FDA Label Image

Figure 7 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 07)

This is a table showing the percentage of patients with certain characteristics in a clinical trial. Placebo had 7 patients and levetiracetam had 101 patients. However, without context on what the characteristics are, it's not possible to provide a useful description beyond this.*

FDA Label Image

Figure 8 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 08)

This text provides information about the percentage of patients who received placebo (N=51) and levetiracetam (N=58). The percentage of patients who received placebo was 19.6%, while the percentage of patients who received levetiracetam was 43.1%. It is unclear from this text what the context or implication of these percentages is.*

FDA Label Image

Figure 9 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 09)

The text represents a graph showing the percentage of patients who received either a placebo or Levetiracetam medication. The graph has percentage values ranging from 0% to 100% on the y-axis and a scale of the number of patients on the x-axis. The placebo group included 84 patients, and the Levetiracetam group included 79. There is not enough information to determine what the medication is prescribed for, or what the percentages represent.*

FDA Label Image

Label Image (Lbl500906378)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.